Trazodone Cost vs. Alternatives: A Class-by-Class Pricing and Efficacy Comparison

What the Trazodone Label Covers

The label calls trazodone a selective serotonin reuptake inhibitor and 5-HT2 receptor antagonist, a triazolopyridine derivative, not a tricyclic [1]. Reported preclinical Ki is 35.6 nM at 5-HT2A and 367 nM at the serotonin transporter, and the label links its alpha-1 blockade to postural hypotension [1]. Generic tablets have been approved since 1987, and the oral solution Raldesy was approved in November 2024 with the same indication [1]. The label has no insomnia indication and no insomnia dose [1].

For depression, the label suggests starting at 150 mg/day in divided doses, raising by 50 mg/day every 3 to 4 days, with an outpatient maximum of 400 mg/day. The label says to take it shortly after a meal or light snack [1].

How the Sleep Evidence Compares

A 2005 review located 18 studies and called the evidence for insomnia very limited: most studies were small, were done in depressed patients, and often lacked objective sleep measures [2].

A 2018 meta-analysis pooled 7 randomized placebo-controlled trials in 429 patients. It found better self-reported sleep quality (SMD -0.41) and fewer awakenings (SMD -0.51). It found no significant difference in sleep efficiency (SMD 0.09), sleep latency, total sleep time or wake after sleep onset. Discontinuation for adverse events and for any cause did not differ significantly from placebo in these short-term trials [3]. Because these trials compared trazodone only with placebo, they do not show how it performs against other sleep drugs.

What the Label Says to Watch For

• Common effects. In outpatient depression trials (trazodone n=157 vs placebo n=158), drowsiness occurred in 41% vs 20%, dry mouth in 34% vs 20%, dizziness or lightheadedness in 28% vs 15%, and blurred vision in 15% vs 4% [1].
• Blood pressure and fainting. In the same trials, hypotension occurred in 4% vs 0% and syncope in 5% vs 1% [1].
• Suicidal thoughts (boxed warning). In pooled short-term antidepressant trials of about 77,000 adults and over 4,400 pediatric patients, the difference from placebo was 14 additional cases per 1,000 treated under age 18, 5 at ages 18 to 24, 1 fewer at 25 to 64, and 6 fewer at 65 and older [1].
• Priapism. The label tells men to stop the drug and get emergency care for any erection lasting more than 4 hours, painful or not [1].
• Heart rhythm. The label states trazodone prolongs the QT/QTc interval, with postmarketing torsades de pointes reported at 100 mg/day or less [1].
• Serotonin syndrome and MAOIs. Serotonin syndrome can occur with trazodone alone. MAOIs, including linezolid and intravenous methylene blue, are contraindicated [1].
• CYP3A4 inhibitors and inducers. The label says to consider a lower trazodone dose with strong CYP3A4 inhibitors and a higher dose with strong CYP3A4 inducers [1].